• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Corcept Therapeutics (NQ: CORT )

    34.28 -0.15 (-0.44%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Aug 22, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 349,155
    Open 34.48
    Bid (Size) 34.28 (1)
    Ask (Size) 34.32 (3)
    Prev. Close 34.43
    Today's Range 34.05 - 35.02
    52wk Range 20.84 - 39.75
    Shares Outstanding 115,926,629
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    NASDAQ:CORT: a strong growth stock preparing for the next leg up?.
    CORCEPT THERAPEUTICS INC (NASDAQ:CORT)—Positioned as a High-Growth Stock, Ready for a Potential Breakout. 
    Via Chartmill
    NASDAQ:CORT is not too expensive for the growth it is showing.
    Don't overlook NASDAQ:CORT—a stock with solid growth prospects and a reasonable valuation. 
    Via Chartmill

    Performance

    YTD
    +41.89%
    +41.89%
    1 Month
    -0.84%
    -0.84%
    3 Month
    +19.78%
    +19.78%
    6 Month
    +58.26%
    +58.26%
    1 Year
    +8.14%
    +8.14%

    More News

    Read More
    Unveiling 8 Analyst Insights On Corcept Therapeutics
    Via Benzinga
    CORT Stock Earnings: Corcept Therapeutics Beats EPS, Beats Revenue for Q2 2024
    Via InvestorPlace
    Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
    From Corcept Therapeutics Incorporated
    Via GlobeNewswire
    6 Analysts Have This To Say About Corcept Therapeutics
    Via Benzinga
    NASDAQ:CORT is not too expensive for the growth it is showing.
    Via Chartmill
    Corcept Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
    Via Benzinga
    Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
    From Corcept Therapeutics Incorporated
    Via GlobeNewswire
    Why NASDAQ:CORT Is a Promising High-Growth Stock in the Midst of Consolidation.
    Via Chartmill
    Investors seeking growth at a reasonable cost should explore NASDAQ:CORT.
    Via Chartmill
    7 Biotech Stocks to Boost Your Portfolio to Peak Health
    Via InvestorPlace
    Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for June 2024
    Via InvestorPlace
    Corcept Announces Presentation of Results From Prevalence Phase of CATALYST Clinical Trial at American Diabetes Association’s Scientific Sessions
    From Corcept Therapeutics Incorporated
    Via GlobeNewswire
    While growth is established for NASDAQ:CORT, the stock's valuation remains reasonable.
    Via Chartmill
    Concerpt Therapeutics Shares Are Trading Lower: What You Need To Know
    Via Benzinga
    Topics Lawsuit
    Exposures Financial Legal
    Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    10 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    Corcept Therapeutics Announces Presentations of Results of Pivotal Phase 3 GRACE Trial Evaluating Relacorilant in Patients with Hypercortisolism (Cushing’s Syndrome)
    From Corcept Therapeutics Incorporated
    Via GlobeNewswire
    Nvidia, Insmed, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
    Via Benzinga
    Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Via Benzinga
    Why Mid-Cap Corcept Therapeutics Stock Trading Higher On Tuesday?
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism (Cushing’s Syndrome)
    From Corcept Therapeutics Incorporated
    Via GlobeNewswire
    While growth is established for NASDAQ:CORT, the stock's valuation remains reasonable.
    Via Chartmill
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.